|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1-4
|
|
pubmed:dateCreated |
1992-10-14
|
|
pubmed:abstractText |
A Gag protein segment of human immunodeficiency virus 1 (HIV-1) has been fused to a C terminally truncated core antigen of hepatitis B virus (HBcAg) using an E. coli expression system. Fusion of 90 amino acids of HIV-1 Gag protein to HBcAg still allowed the formation of capsids presenting on their surface epitopes of HIV-1 core protein, whereas fusion of 317, 189, or 100 amino acids of Gag prevented self-assembly of chimeric particles. Mice immunized with recombinant particles emulsified with Freund's complete adjuvant (CFA) or aluminium hydroxide developed high anti-HBcAg titers. However, anti-HIVp24 antibodies were detected only in mice inoculated with immunogen emulsified with CFA.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AIDS Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/Freund's Adjuvant,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Core Protein p24,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Core Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Hepatitis Vaccines
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0304-8608
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
126
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
321-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1381912-AIDS Vaccines,
pubmed-meshheading:1381912-Animals,
pubmed-meshheading:1381912-Blotting, Western,
pubmed-meshheading:1381912-Epitopes,
pubmed-meshheading:1381912-Escherichia coli,
pubmed-meshheading:1381912-Freund's Adjuvant,
pubmed-meshheading:1381912-HIV Antibodies,
pubmed-meshheading:1381912-HIV Core Protein p24,
pubmed-meshheading:1381912-HIV-1,
pubmed-meshheading:1381912-Hepatitis B Antibodies,
pubmed-meshheading:1381912-Hepatitis B Core Antigens,
pubmed-meshheading:1381912-Hepatitis B Vaccines,
pubmed-meshheading:1381912-Hepatitis B virus,
pubmed-meshheading:1381912-Humans,
pubmed-meshheading:1381912-Mice,
pubmed-meshheading:1381912-Microscopy, Electron,
pubmed-meshheading:1381912-Plasmids,
pubmed-meshheading:1381912-Recombinant Fusion Proteins,
pubmed-meshheading:1381912-Vaccines, Synthetic,
pubmed-meshheading:1381912-Viral Hepatitis Vaccines
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen.
|
|
pubmed:affiliation |
Institute of Virology, Charité, Berlin, Federal Republic of Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
